Efficacy of probiotics in Helicobacter pylori eradication therapy

A clinical trial study for comparison of probiotic combined with standard triple therapy and standard triple therapy in Helicobacter pylori eradication in dyspeptic patients between 15-40 years old with positive fecal antigen.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016060628304N1

Enrollment

176

Registered

2016-07-11

Start date

2015-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori in dyspeptic patients. ,Gastritis and duodenitis,Gastrojejunal ulcer,Duodenal ulcer,Gastric ulcerPeptic ulcer, site unspecified,Dyspepsia

Interventions

Intervention 1: Control group: they were prescribed standard regimen for H.pylori eradication (pantoprazole (40 mg, b.i.d.), amoxicillin (1000 mg b.i.d.), clarithromycin(500 mg b.i.d.) for 10 days plu

Treatment - Drugs

Control group: they were prescribed standard regimen for H.pylori eradication (pantoprazole (40 mg, b.i.d.), amoxicillin (1000 mg b.i.d.), clarithromycin(500 mg b.i.d.) for 10 days plus a capsule look

Intervention Group: they were prescribed standard regimen for H.pylori eradication (pantoprazole (40 mg, b.i.d.), amoxicillin (1000 mg b.i.d.), clarithromycin(500 mg b.i.d.) for 10 days plus 500mg pro

Eligibility

Sex/Gender

All

Age

15 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 15-40; informed consent; dyspepsia symptoms; Positive fecal H.pylori antigen. Exclusion Criteria: recent use of any antiboitics during last 2 weeks; recent use of PPIs during past 1 month; any eradicative therapy for helicobacter pylori; any approved malignancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fecal antigen. Timepoint: 1 month and 6 month after intervention. Method of measurement: ELISA test.	—

Secondary

Measure	Time frame
Gastrointestinal adverse effects. Timepoint: 1 month after intervention. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Pourmohammad

Tabriz University of Medical Sciences

alirmd@outlook.com+98 41 3381 4472

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026